NEW YORK (GenomeWeb News) – Waters today reported that its revenues in the second quarter were up 7 percent, driven by broad-based pharmaceutical demand and strong US sales.

The company posted Q2 revenues of $481.8 million, up from $451.1 million in Q2 2013 and beating the average Wall Street estimate of $476.1 million.

It reported a profit of $96.5 million, or $1.13 per share, during the quarter, compared to a profit of $89.3 million, or $1.03 per share, a year ago. On a non-GAAP basis, Waters had EPS of $1.22, beating the average analyst estimate of $1.21.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: gene fusion in premature ovarian failure, population patterns in the Franciscana dolphin, and more.

A National Science Foundation-funded project aims to give researchers access to a network many times faster than the Internet.

Bioethicists weigh the idea of charging patients to take part in clinical research, coming down against the approach.

Cornell's Christopher Mason and his colleagues correct their New York City microbiome study to emphasize "the difference between matching fragments of DNA from a species and a pathogen."